2020 ASCO Virtual Direct™ Highlights
ASCO 2020 Updates on IO in H&N Cancers: Cetuximab + Nivo, Cetuximab + Monalizumab, Pembro + ICOS Agonist: How Do They Affect Clinical Activities and Is ORR Improved?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jessica Bauman
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jessica Bauman
Login to view comments.
Click here to Login
